%0 Journal Article
%A Salvador-Martín, Sara
%A Raposo-Gutiérrez, Irene
%A Navas-López, Víctor Manuel
%A Gallego-Fernández, Carmen
%A Moreno-Álvarez, Ana
%A Solar-Boga, Alfonso
%A Muñoz-Codoceo, Rosana
%A Magallares, Lorena
%A Martínez-Ojinaga, Eva
%A Fobelo, María J.
%A Millán-Jiménez, Antonio
%A Rodriguez-Martinez, Alejandro
%A Vayo, Concepción A.
%A Sánchez, Cesar
%A Tolin, Mar
%A Bossacoma, Ferrán
%A Pujol-Muncunill, Gemma
%A González de Caldas, Rafael
%A Loverdos, Inés
%A Blanca-García, José A.
%A Segarra, Oscar
%A Eizaguirre, Francisco J.
%A García-Romero, Ruth
%A Merino-Bohórquez, Vicente
%A Sanjurjo-Sáez, María
%A López-Fernández, Luis A.
%T Gene Signatures of Early Response to Anti-TNF Drugs in Pediatric Inflammatory Bowel Disease
%D 2020
%U http://hdl.handle.net/10668/3700
%X Around a 20-30% of inflammatory bowel disease (IBD) patients are diagnosed before they are 18 years old. Anti-TNF drugs can induce and maintain remission in IBD, however, up to 30% of patients do not respond. The aim of the work was to identify markers that would predict an early response to anti-TNF drugs in pediatric patients with IBD. The study population included 43 patients aged <18 years with IBD who started treatment with infliximab or adalimumab. Patients were classified into primary responders (n = 27) and non-responders to anti-TNF therapy (n = 6). Response to treatment could not be analyzed in 10 patients. Response was defined as a decrease in over 15 points in the disease activity indexes from week 0 to week 10 of infliximab treatment or from week 0 to week 26 of adalimumab treatment. The expression profiles of nine genes in total RNA isolated from the whole-blood of pediatric IBD patients taken before biologic administration and after 2 weeks were analyzed using qPCR and the 2-∆∆Ct method. Before initiation and after 2 weeks of treatment the expression of SMAD7 was decreased in patients who were considered as non-responders (p value < 0.05). Changes in expression were also observed for TLR2 at T0 and T2, although that did not reach the level of statistical significance. In addition, the expression of DEFA5 decreased 1.75-fold during the first 2 weeks of anti-TNF treatment in responders, whereas no changes were observed in non-responders. Expression of the SMAD7 gene is a pharmacogenomic biomarker of early response to anti-TNF agents in pediatric IBD. TLR2 and DEFA5 need to be validated in larger studies.
%K Biomarker
%K Gene expression
%K Infliximab
%K Adalimumab
%K Ulcerative colitis
%K Crohn’s disease
%K Biomarcadores
%K Expresión génica
%K Colitis ulcerosa
%K Enfermedad de Crohn
%~